Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5278854
Max Phase: Preclinical
Molecular Formula: C55H86N16O17
Molecular Weight: 1243.39
Associated Items:
ID: ALA5278854
Max Phase: Preclinical
Molecular Formula: C55H86N16O17
Molecular Weight: 1243.39
Associated Items:
Canonical SMILES: CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](N)CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)O
Standard InChI: InChI=1S/C55H86N16O17/c1-28(2)19-33(57)45(78)65-36(21-30-12-14-32(73)15-13-30)48(81)68-39(20-29(3)4)53(86)71-18-8-11-42(71)52(85)64-34(9-5-6-16-56)46(79)66-37(22-31-25-60-27-62-31)49(82)70-41(26-72)51(84)67-38(23-43(74)75)50(83)63-35(10-7-17-61-55(58)59)47(80)69-40(54(87)88)24-44(76)77/h12-15,25,27-29,33-42,72-73H,5-11,16-24,26,56-57H2,1-4H3,(H,60,62)(H,63,83)(H,64,85)(H,65,78)(H,66,79)(H,67,84)(H,68,81)(H,69,80)(H,70,82)(H,74,75)(H,76,77)(H,87,88)(H4,58,59,61)/t33-,34-,35-,36-,37-,38-,39-,40-,41-,42-/m0/s1
Standard InChI Key: NHJUFNWIIVOTIH-NUDUWCFGSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1243.39 | Molecular Weight (Monoisotopic): 1242.6357 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Ahamad S, Bhat SA.. (2022) Recent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia Treatment., 65 (23.0): [PMID:36446632] [10.1021/acs.jmedchem.2c01290] |
Source(1):